SCHEMBL17479807

SCHEMBL17479807

O=S(=O)(c1cccc(-c2nc3ccccc3o2)c1)N1CCCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.60
▸ GAA P10253 3/20 0.60
▸ USP2 O75604 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ SMN1; SMN2 Q16637 4/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ MAPK1 P28482 3/20 0.57
▸ TSHR P16473 4/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ MAPT P10636 1/20 0.57
▸ NPSR1 Q6W5P4 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ THRB P10828 1/20 0.51
▸ PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19205947 0.91 MAPT (0.61) ALDH1A1GAAUSP2L3MBTL1SMN1; SMN2
SCHEMBL17479721 0.86 MAPK1 (0.56) ALDH1A1GAAUSP2L3MBTL1SMN1; SMN2
SCHEMBL3948026 0.79 UTRN (0.65) GAAL3MBTL1SMN1; SMN2MEN1KMT2A
SCHEMBL16459106 0.76 UTRN (0.64) ALDH1A1USP2SMN1; SMN2MEN1KMT2A
SCHEMBL28837241 0.75 TSHR (0.49) ALDH1A1GAAUSP2L3MBTL1SMN1; SMN2
SCHEMBL2384769 0.75 USP2 (0.55) ALDH1A1GAAUSP2L3MBTL1LMNA
SCHEMBL17479797 0.74 MEN1 (0.53) ALDH1A1GAAUSP2SMN1; SMN2MEN1
SCHEMBL376001 0.74 ALDH1A1 (0.64) ALDH1A1GAAUSP2SMN1; SMN2MEN1
SCHEMBL28160890 0.74 KMT2A (0.57) ALDH1A1GAAUSP2SMN1; SMN2MEN1
SCHEMBL28558754 0.73 CYP2C9 (0.51) ALDH1A1GAAUSP2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP disclosed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US disclosed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US disclosed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP disclosed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS FLT3, CSF1R, CSF3R ALDH1A1 2419/4885GAA 3631/4885USP2 3980/4885
US-10065937-B2 FLT3 receptor antagonists FLT3, CSF1R, CSF3R ALDH1A1 2419/4885GAA 3631/4885USP2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback